Posttransplant lymphoproliferative disease after pediatric solid organ transplantation
Standard
Posttransplant lymphoproliferative disease after pediatric solid organ transplantation. / Mynarek, Martin; Schober, Tilmann; Behrends, Uta; Maecker-Kolhoff, Britta.
in: Clin Dev Immunol, Jahrgang 2013, 01.01.2013, S. 814973.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Posttransplant lymphoproliferative disease after pediatric solid organ transplantation
AU - Mynarek, Martin
AU - Schober, Tilmann
AU - Behrends, Uta
AU - Maecker-Kolhoff, Britta
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Patients after solid organ transplantation (SOT) carry a substantially increased risk to develop malignant lymphomas. This is in part due to the immunosuppression required to maintain the function of the organ graft. Depending on the transplanted organ, up to 15% of pediatric transplant recipients acquire posttransplant lymphoproliferative disease (PTLD), and eventually 20% of those succumb to the disease. Early diagnosis of PTLD is often hampered by the unspecific symptoms and the difficult differential diagnosis, which includes atypical infections as well as graft rejection. Treatment of PTLD is limited by the high vulnerability towards antineoplastic chemotherapy in transplanted children. However, new treatment strategies and especially the introduction of the monoclonal anti-CD20 antibody rituximab have dramatically improved outcomes of PTLD. This review discusses risk factors for the development of PTLD in children, summarizes current approaches to therapy, and gives an outlook on developing new treatment modalities like targeted therapy with virus-specific T cells. Finally, monitoring strategies are evaluated.
AB - Patients after solid organ transplantation (SOT) carry a substantially increased risk to develop malignant lymphomas. This is in part due to the immunosuppression required to maintain the function of the organ graft. Depending on the transplanted organ, up to 15% of pediatric transplant recipients acquire posttransplant lymphoproliferative disease (PTLD), and eventually 20% of those succumb to the disease. Early diagnosis of PTLD is often hampered by the unspecific symptoms and the difficult differential diagnosis, which includes atypical infections as well as graft rejection. Treatment of PTLD is limited by the high vulnerability towards antineoplastic chemotherapy in transplanted children. However, new treatment strategies and especially the introduction of the monoclonal anti-CD20 antibody rituximab have dramatically improved outcomes of PTLD. This review discusses risk factors for the development of PTLD in children, summarizes current approaches to therapy, and gives an outlook on developing new treatment modalities like targeted therapy with virus-specific T cells. Finally, monitoring strategies are evaluated.
KW - Adolescent
KW - Child
KW - Child, Preschool
KW - Humans
KW - Lymphoproliferative Disorders
KW - Organ Transplantation
KW - Prognosis
KW - Risk Factors
U2 - 10.1155/2013/814973
DO - 10.1155/2013/814973
M3 - SCORING: Journal article
C2 - 24174972
VL - 2013
SP - 814973
ER -